|Systematic (IUPAC) name|
|Trade names||former Mandol|
|Pregnancy cat.||B1 (AU)|
|Legal status||POM (UK) Discontinued (US)|
|Excretion||Mostly renal, as unchanged drug|
|Mol. mass||462.505 g/mol|
| (what is this?)
Cefamandole (INN, also known as cephamandole) is a second-generation broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally.
Cefamandole is no longer available in the United States.
The chemical structure of cefamandole, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase)(vitamin K supplement is recommended during therapy) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.
Spectrum of Bacterial Susceptibility and Resistance
Generally Diploccus pneumoniae, Fusobacterium and Neisseria gonorrhoeae are susceptible to Cefamandole, while bacteroides, pseudomonas and serratia are resistant to Cefamandole. Citrobacter, enterbacter and escherichia coli have developed resistance to Cefamandole in varying degrees. For the detailed minimum inhibition concentration information, please refer to Cefamandole Susceptibility and Resistance Data sheet.
CO2 is generated during the normal constitution of cefamandole & ceftazidim resulting in explosive like reaction in syringe
- "Cefamandole Susceptibility and Resistance Data". Retrieved 21 July 2013.
- Stork CM (2006). "Antibiotics, antifungals, and antivirals". In Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA (eds.). Goldfrank's toxicologic emergencies. New York: McGraw-Hill. p. 847. ISBN 0-07-143763-0. Retrieved 2009-07-03.